Eli Lilly (LLY) stock

Cardiometabolic and cancer drugsGLP-1 and obesity drugs

Worth $1.2T

Pre-market

$1,376.50

+1.66%

Drug products, worth $1.2TGLP-1 and obesity drugs

Close $1,354.00 -0.79%

As of 8:20 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Excellent

In its industry

#2of 90

Pharma

Checks firing

5of 14

Trending up

From 52-week high

-6.8%

under its best in a year

LLY's Quality Score fell 1 point on Fri, Nov 6, to 18. Trading went back to normal after a busy day.

Follow LLY's trial news. Pro members can get an alert when Eli Lilly files news, and see its trials, share raises, and its CEO's filings.

Get an alert when LLY files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ1 2027“…pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027…”Filing with regulators · SEC filing · Aug 5

Why LLY rose on Oct 29

Up 7% on Oct 29, and still 5% over its Oct 28 close.

“In Q3 2026, worldwide revenue was $24.4 billion, an increase of 39% compared with Q3 2025, driven by a 53% increase in volume”

Eli Lilly's Oct 29 release said

Sources: Price history, Oct 29, 2026; Company release, Oct 29, 2026

1 more reason, free with an account →4 more reasons why LLY rose on Oct 29, from its filings, with the other side, the company's words, the timeline, and its peers, for Pro members.

Key facts on LLY

Key facts on LLY
Profit tripled	$6.24B → $20.64B in 3 years
Latest filing	8-K, Oct 29 Reported its quarterly results

1 more reason behind LLY's 18, free with an account →4 more reasons behind LLY's 18, for Pro members.

LLY in the news

ReportReports Thursday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 4 of its last 4 reports, +7.9% on average. Past reports ›

Big story

Guidance

Eli Lilly jumps on earnings beat, raised revenue guidance

LLY closed +6.6% that day on 1.8x normal volume.

Reported by Yahoo Finance · covered by 13 outlets

Get an alert on LLY's next big story →

Outlet counts from the GDELT Project. The move is what LLY did that session, not a claim about why.

What's next

Mon Dec 7: Eli Lilly Innovation Day 2026Date confirmed.

2 more dates ahead: the conference and dividend dates, for Pro members.

LLY catalysts

Coming up

After its last 4 reports it closed +7.9% on average, higher 4 of 4 times.

4 more coming up and 59 past catalysts since 2019, with sizes and sources, for Pro members.

What's next for LLY

Next step the company has named

Q1 2027“…global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027.”Filing with regulators · SEC filing · Aug 5

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway: SURPASS-T1D-2Phase 3 · Active · 465 people · main data estimated Nov 2026 · NCT06962280

230 more trials, 13 with data due this year, 58 drugs past Phase 1, 40 drug news items, and 27 filings, for Pro members.

Dilution on the horizon

Shelf registration (S-3ASR, filed Feb 19, 2025)

For Pro members: the amounts, and the share count against a year ago.

Insiders

EVP, GC & Secretary Anat Hakim sold 5,000 shares on Nov 2, under a planned sale. 4 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when David Ricks buys or sells

For Pro members: every trade, and David Ricks’s 7 filings and quotes.

Get an alert when LLY files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why LLY scores 18

Excellentfor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means

+5Chart checks 5 of 14 firing right now, one point each
+4Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, at a multi-⁠year high

Run-up adds
Size adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Persistence adds

No effect today: Dilution, Volatility, Cash flow, and News.

What every line is worth, and the reason behind it, on LLY and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:20 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when LLY's Quality Score turns up

A free account. No card.

How LLY ranks in Pharma

LLY is #2 of 90 by Quality Score.

How LLY ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	8/14	24
2	LLYEli Lilly	5/14	18
3	CRONCronos	5/14	18
	JNJJohnson & Johnson		Open for its score
	KARDKardigan		Open for its score
	LNTHLantheus		Open for its score
	LQDALiquidia		Open for its score

Net income over four quarters: LLY $27.6B, BMY $9.24B.

When does LLY report earnings, and what happens after?

Reports Thu Nov 12, before the open (in 3 days). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What LLY reported on Oct 29, 2026

The quarter

Sales of $24.4B, 39% more than a year ago; a profit of $7.22 a share, from $6.21.

“In Q3 2026, worldwide revenue was $24.4 billion, an increase of 39% compared with Q3 2025, driven by a 53% increase in volume, partially offset by a 15% decrease in realized prices.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Productup 39%	$23B31%	$21B31%	$16B31%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 29)

21 more lines, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
FY2026
Non-GAAP EPS	$35.00 to $36.00raised

Figures as filed (SEC filing, Oct 29)

The numbers

Market value: $1.2T; today
Sales: $86B; up 45.5% on the year

Sales grew 22% a year over 5 years, fiscal 2020 to 2025.

Pays $6.92 a share a year.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on LLY: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+9.8%+4.9%+6.6%

Apr 30Aug 5Oct 29

Reported	When	Gap	Reaction	5 days
Oct 29, 2026Before open	Before open	+3.5%	+6.6%	+10.1%
Aug 5, 2026Before open	Before open	+5.2%	+4.9%	+8.9%
Apr 30, 2026Before open	Before open	+5.6%	+9.8%	+16.0%

LLY closed higher after 4 of its last 4 reports.

All 4 reports, and LLY's Quality Score going into each

Everyone reporting earnings this week

LLY sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $65B. It made a profit in each of the eight years.

LLY has 5 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on LLY, and all 14 on every stock.Get in free →

LLY RSI on Nov 6: 61.1, above its 50-day and 200-day averages

Not scored

RSI 61.1, MACD above signal, above both averages. Not scored.13 readings

The deep dive on LLY

What it does and how it makes money3 findingsIt kept 39 cents of each dollar of sales in fiscal 2025: $25.7B of profit before tax on $65.2B of sales.Annual report, filed Feb 12, 2026
Where it stands3 findingsFor Pro members3 findings on where LLY stands: its cash, debt, and share count, for Pro members
What changed in its filings5 findings"In August 2026, we filed patent infringement actions against these companies in the U.S. District Court for the District of Delaware." (10-Q for the quarter to Sep 30, 2026)SEC filing · Oct 29, 2026A new heading in its "Risk Factors" this year: "We and our products face intense competition, and such competition could have a material adverse effect on our business." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 12, 2026, against the one of Feb 19, 2025
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades LLY, for Pro members
Against its closest peers1 peerNet income over four quarters: LLY $27.6B, BMY $9.24B.

11 more findings on LLY, each with its source, for Pro members.

LLY share count over time

Shares: 0.6% fewer than a year ago (to Sep 30).

Shares of LLY outstanding, as filed
Shares outstanding	As of
940.7M	Oct 26, 2026
941.4M	Aug 3, 2026
941.7M	Apr 27, 2026
943.4M	Feb 9, 2026

Offerings, shelves, and splits of LLY, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Feb 19, 2025

LLY insider trades

LLY trades by Congress and the executive branch

16 trades disclosed in the last six months. The newest:

BuyRo Khanna$1K to $15KHousetraded Sep 4, disclosed Oct 7(33 days later)

BuyRo KhannaHouse$1K to $15Ktraded Sep 4, disclosed Oct 7(33 days later)

All 16 trades on LLY disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

LLY's officers and directors

Officers and directors with a Form 4 in the last 12 months.

David A. RicksPresident, Chair, and CEO · no trades on file
Lucas MontarceEVP & CFO · no trades on file
Anat HakimEVP, GC & Secretary · 2 trades
Donald A. ZakrowskiSVP, Finance, & CAO · 2 trades
Ilya YuffaEVP&Pres, LLY USA&Global Capab · 1 trade
Patrik JonssonEVP & President, LLY Int'l · 1 trade
Adrienne S. BrownEVP, President LLY Imm · no trades on file
Daniel SkovronskyEVP, CS&PO & Pres. LRL · no trades on file

16 more officers and directors file at LLY.

See insider trades by person

Which ETFs hold LLY?

In ETFs: LLY is 4.6% of VIG, 3.6% of SCHG, and 1.7% of VOO, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.

About Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

50,000 employeesIndianapolis, INlilly.com

What Eli Lilly says it competes with

“Our products compete globally with many other pharmaceutical products in highly competitive markets.”

From its annual report, SEC filing · Feb 12, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on LLY and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move LLY's score: 3 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 7Ro Khanna bought LLY$1K to $15K, disclosed Oct 7

Alerts are optional.

See LLY's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: LLY's Quality Score is 18 (Excellent), #2 of 90 in Pharma.

What does LLY's Quality Score say?

LLY scores 18 today, which Breakaway calls Excellent. It is #2 of 90 in Pharma by Quality Score, with 5 of 14 chart checks firing. Up 7% on Oct 29, and still 5% over its Oct 28 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is LLY's Quality Score?

LLY scores 18 today, which Breakaway calls Excellent (15 to 19). That is #2 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LLY's 18.

When does LLY report earnings?

Reports Thu Nov 12, before the open, a date the company confirmed. LLY closed higher after 4 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.